[ET Net News Agency, 30 December 2021] Livzon Pharmaceutical Group Inc. (01513) said
Shanghai Livzon Pharmaceutical Manufacturing Co., Ltd., a subsidiary of the company, was
granted the "Approval Notice for Clinical Trial on Drug". It was approved and issued by
the China National Medical Products Administration to approve the commencement of the
clinical trial of Alarelin Acetate Microspheres for Injection.
The accumulated direct investment expenses in R&D of Alarelin Acetate Microspheres for
Injection amounted to approximately RMB17.8185 million. (RC)